Pravastatin sodium cas no:81131-70-6
Synonyms: Mevalotin;Pravachol;Pravachol (TN);Pravastatine [French];1-Naphthaleneheptanoic acid,1,2,6,7,8,8a-hexahydro-a,?,6-trihydroxy- 2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-,monosodium salt,(aR,?R,1S,2S,6S,8S,8aR)-;Pravastatina [Spanish];Pravastatinum [Latin];1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, (1S-(1alpha(betas*,deltas*),2alpha,6alpha,8beta(R*),8aalpha))-;sodium (3R,5R)-7-[(1S,2R,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxy-heptanoate;1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-((2S)-2-methyl-1-oxobutoxy)-, (betaR,deltaR,1S,2S,6S,8S,8aR)-;Lipostat;SQ 31000;Paravastatin;
NamePravastatin sodium
CAS81131-70-6
SynonymsMevalotin;Pravachol;Pravachol (TN);Pravastatine [French];1-Naphthaleneheptanoic acid,1,2,6,7,8,8a-hexahydro-a,?,6-trihydroxy- 2-methyl-8-[(2S)-2-methyl-1-oxobutoxy]-,monosodium salt,(aR,?R,1S,2S,6S,8S,8aR)-;Pravastatina [Spanish];Pravastatinum [Latin];1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-(2-methyl-1-oxobutoxy)-, (1S-(1alpha(betas*,deltas*),2alpha,6alpha,8beta(R*),8aalpha))-;sodium (3R,5R)-7-[(1S,2R,6S,8S,8aR)-6-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxy-heptanoate;1-Naphthaleneheptanoic acid, 1,2,6,7,8,8a-hexahydro-beta,delta,6-trihydroxy-2-methyl-8-((2S)-2-methyl-1-oxobutoxy)-, (betaR,deltaR,1S,2S,6S,8S,8aR)-;Lipostat;SQ 31000;Paravastatin;
Molecular FormulaC23H35NaO7
Molecular Weight446.50957
AppearanceWhite Crystalline Powder
storage temp2-8°C
Globally Harmonized System of Classification adn Labelling of Chemicals(GHS)
Hazardclass9
Hazard F: Flammable;C: Corrosive;
Risk R11
Safety
Moderately toxic by intravenous and intraperitoneal. Low toxicity by ingestion. Human systemic effects. When heated to decomposition it emits acrid smoke and irritating vapors.
Safety Information of Pravastatin sodium (CAS NO.81131-70-6):
Hazard Codes:?
F,
C
Risk Statements: 11-34?
R11:Highly flammable.?
R34:Causes burns.
Safety Statements: 16-26-36/37/39-45?
S16:Keep away from sources of ignition.?
S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.?
S36/37/39:Wear suitable protective clothing, gloves and eye/face protection.?
S45:In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.)
RIDADR: 3077
WGK Germany: 2
RTECS: QJ7185000
HazardClass: 9
PackingGroup: III
| Organism |
Test Type |
Route |
Reported Dose (Normalized Dose) |
Effect |
Source |
| man |
TDLo |
oral |
16mg/kg/8W-I (16mg/kg) |
LIVER: "JAUNDICE, CHOLESTATIC"
LIVER: LIVER FUNCTION TESTS IMPAIRED
SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE" |
American Journal of Emergency Medicine. Vol. 17, Pg. 1388, 1999. |
| mouse |
LD50 |
intravenous |
2011mg/kg (2011mg/kg) |
SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE
LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES
BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) |
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 15, Pg. 4949, 1987. |
| mouse |
LD50 |
oral |
8939mg/kg (8939mg/kg) |
SENSE ORGANS AND SPECIAL SENSES: LACRIMATION: EYE
GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"
BLOOD: CHANGES IN SPLEEN |
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 15, Pg. 4949, 1987. |
| mouse |
LD50 |
subcutaneous |
2975mg/kg (2975mg/kg) |
SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE
LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES
BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) |
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 15, Pg. 4949, 1987. |
| rat |
LD50 |
intravenous |
440mg/kg (440mg/kg) |
BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX)
LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) |
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 15, Pg. 4949, 1987. |
| rat |
LD50 |
oral |
> 12gm/kg (12000mg/kg) |
? |
Yakkyoku. Pharmacy. Vol. 40, Pg. 2351, 1989. |
| rat |
LD50 |
subcutaneous |
3172mg/kg (3172mg/kg) |
BEHAVIORAL: ATAXIA
LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES
SKIN AND APPENDAGES (SKIN): HAIR: OTHER |
Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 15, Pg. 4949, 1987. |
| rat |
LDLo |
intraperitoneal |
400mg/kg (400mg/kg) |
? |
Biochemistry and Molecular Biology International. Vol. 47, Pg. 519, 1999. |
| women |
TDLo |
oral |
16800ug/kg (16.8mg/kg) |
BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) |
Lancet. Vol. 340, Pg. 910, 1992. |
| women |
TDLo |
oral |
30mg/kg/21W-I (30mg/kg) |
BEHAVIORAL: MUSCLE WEAKNESS
BLOOD: "CHANGES IN SERUM COMPOSITION (E.G., TP, BILIRUBIN, CHOLESTEROL)"
SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE" |
New England Journal of Medicine. Vol. 327, Pg. 649, 1992. |
